Published in Food and Drug Law Weekly, October 27th, 2006
The president & CEO of Bioniche Life Sciences, Inc., Graeme McRae, stated, "Bioniche had an eventful year. The U.S. Food and Drug Administration (FDA) approved our two phase III trial protocols using Urocidin in the treatment of non-muscle invasive bladder cancer. In addition, we were granted fast track status for the refractory protocol, meaning that, when data from the refractory study becomes available, we can expect an expedited review of our Biologics Licensing Application for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.